Targeted drug shows promise in rare advanced kidney cancer

(Dana-Farber Cancer Institute) Some patients with a form of advanced kidney cancer benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by Dana-Farber Cancer Institute scientists.